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Background: Postprandial hyperglycemia is a known risk factor for the development of several health disorders
including type 2 diabetes, obesity, oxidative stress, and cardiovascular diseases. One encouraging approach for a
better control of postprandial glycemia is to reduce carbohydrate digestion. Cinnamon extracts have been known
for managing blood glucose. However, their effects on inhibiting digestion of carbohydrate have been poorly
analyzed to date. The aim of this study was to investigate the acute effect of a specific Ceylon cinnamon
hydro-alcoholic extract (CCE) on carbohydrate digestion and post-meal blood glucose reduction.
Methods: In vitro enzymatic assays and in vivo starch tolerance tests in rats were designed as preclinical assays.
Then, a randomized, double-blind, placebo-controlled, cross-over clinical trial was conducted in 18 healthy female
and male volunteers. Following the intake of 1 g of CCE, the subjects ate a standardized meal. Blood samples were
collected during the 2 hours following the meal to measure glucose and insulin concentrations. Areas under the
curves were calculated and statistical differences between the CCE and placebo groups were analyzed using the
Mann Whitney-Wilcoxon test.
Results: CCE has demonstrated in the in vitro study that it inhibited pancreatic alpha-amylase activity with an
IC50 of 25 μg/mL. In the in vivo study, CCE was shown to acutely reduce the glycemic response to starch in a
dose-dependent manner in rats. This effect was significant from the dose of 12.5 mg/kg of body weight. In both,
the in vitro and in vivo studies, the hydro-alcoholic extract has shown to be more efficacious than the aqueous
extract. In the human clinical trial, 1 g of CCE lowered the area under the curve of glycemia between 0 and
120 min by 14.8% (P = 0.15) and between 0 and 60 min by 21.2% (P < 0.05) compared to the placebo. This effect
occurred without stimulating insulin secretion. No adverse effects were reported.
Conclusion: These results suggest that Ceylon cinnamon hydro-alcoholic extract (CCE) may provide a natural and
safe solution for the reduction of postprandial hyperglycemia and therefore help to reduce the risks of developing
metabolic disorders.
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A large and growing body of evidence indicates that
postprandial hyperglycemia is a contributing factor for
the development of several health related disorders [1,2].
Firstly, postprandial hyperglycemia has been shown to
begin prior to type 2 diabetes occurring [3-5] and its con-
trol is essential for achieving recommended glycosylated
hemoglobin levels (representing mean glycemia over a
prolonged period of time) since control of fasting hy-
perglycemia only is necessary but usually insufficient [4].
The human and economic cost of diabetes could be sig-
nificantly reduced through prevention, and the control of
postprandial glycemia is a good area to target for this
purpose. Secondly, several studies suggest that low gly-
cemic index diets, inducing lower postprandial glycemic
responses, improve lipid profiles and body weight gain
patterns [6-9]. These diets decrease total fat mass [7,8],
total cholesterol and LDL cholesterol, thus improving
plasma lipid profiles in healthy subjects [6,7,9]. Thirdly, a
causal relationship has been demonstrated between post-
prandial hyperglycemia and oxidative stress [10], carotid
intima-media thickness and endothelial dysfunction [11],
and increased the risk of cardiovascular diseases occurring
[12,13]. Moreover, results from the Baltimore Longitudinal
Study on aging showed that impaired glucose tolerance
(IGT), by itself, increases the risk of cardiovascular dis-
eases occurring [14]. Accordingly, each of these studies
provide relevance for reducing postprandial hyperglycemia
in order to prevent several metabolic disorders.
One interesting approach for limiting postprandial
hyperglycemia is to reduce or slow down dietary carbo-
hydrate digestion. Inhibiting the enzymes involved, such
as the α-amylase and α-glucosidase enzymes, is a powerful
therapeutic target for managing the postprandial glycemic
response. Also, α-glucosidase inhibitors are one of the
anti-diabetic drug families, of which Acarbose is the most
well-known. These medications have a very strong effect
and are suitable for treating type 2 diabetes [15] but also
induce gastrointestinal side effects that limit their use in a
preventive approach [16]. Consequently, several scientists
are researching and developing nutritional strategies to
finely regulate postprandial glycemia, without inducing
adverse events in the gastric tract [17].
Cinnamon, one of the oldest spices known world-wide, is
obtained from the inner bark of different tree species of the
genus Cinnamomum. Chinese cinnamon (Cinnamomum
cassia or Cinnamomum aromaticum), coming from China
and Southern and Eastern Asia, is more widely used, not-
ably in food, but it contains high level of coumarin, a po-
tentially harmful molecule [18], unlike Ceylon cinnamon
(Cinnamomum zeylanicum or Cinnamomum verum),
coming from Sri Lanka and Madagascar, which contains
only traces of coumarin [19]. Cinnamon has been exten-
sively studied for the regulation of blood glucose. Severalclinical trials have evaluated the chronic effects of cinna-
mon [20,21] or cinnamon extracts [22,23] on subjects suf-
fering from type 2 diabetes. However, the results of several
meta-analyses remain controversial, some indicating that
cinnamon causes a significant decrease in fasting blood
glucose [24,25] where another reports that cinnamon does
not improve fasting blood glucose, HbA1c or lipid param-
eters in type 2 diabetic subjects [26].
Regarding the acute effect of cinnamon on postpran-
dial glycemia, the available literature is quite puzzling. In
vivo, a methanol extract of Ceylon cinnamon reduced
the glycemic response to maltose and sucrose in normal
and diabetic rats but had no effect on glucose loading,
thus suggesting a specific effect of this extract on disacchar-
ide digestion through the inhibition of the α-glucosidase
enzyme [27]. Some clinical studies have evaluated the
acute effects of ground cinnamon bark on postprandial
plasma glucose. Wickenberg et al. did not observe any
significant effect with 6 g of Ceylon cinnamon during a
standard oral glucose tolerance test (OGTT) in subjects
with IGT [28], and Markey et al. saw no effect of 3 g of
Ceylon cinnamon in response to a high fat breakfast in
healthy volunteers [29]. For Cassia species, Hlebowicz
et al. did show that the ingestion of 6 g of Cassia cinna-
mon reduced the blood glucose response to a test meal
[30] while 3 g did not [31]. Magistrelli et al. confirmed the
acute effect of 6 g Cassia cinnamon on postprandial gly-
cemia in both: normal-weight and obese adults [32].
As illustrated by all of the above, some published clinical
studies have assessed the acute effect of raw cinnamon
powder from different cinnamon species on postprandial
glycemia. However, to our knowledge, the acute effect of
cinnamon extracts has not been clinically researched. As a
result, we have identified a specific hydro-alcoholic Ceylon
cinnamon extract. This publication presents the effects
that the extract has on the pancreatic α-amylase activity
and on the glucose response to starch in rodents as well
as humans as tested in a randomized, placebo-controlled,
cross-over clinical trial in healthy subjects.
Methods
Cinnamon extracts
The Ceylon cinnamon extract (CCE) tested in this study
is manufactured by Dialpha (commercially available under
the MealShape trademark). It is a hydro-alcoholic extract of
Ceylon cinnamon bark (10:1), also called true Cinnamon,
Cinnamomum zeylanicum, or Cinnamomum verum. The
dried and milled cinnamon barks were extracted with a
50:50 water-ethanol solution during a 2 hour period. The
extraction mixture was filtrated in order to remove any
remaining solids, then concentrated under reduced pres-
sure through evaporation of the ethanol and most of the
water, before finally being dried in a vacuum drier to
obtain a fine brown powder: CCE.
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nols, CCE’s main active compounds. These polyphenols
are mainly constituted of procyanidin oligomers which
are composed of catechin and epicatechin monomers.
The total polyphenol content was measured by a colori-
metric method using a Folin-Ciocalteu reagent as per the
ISO14502-1 method.
In order to compare the potential impact of the ex-
traction solvent on the acute reduction of the starch
glycemic response, an aqueous cinnamon extract was
also produced from the same Ceylon cinnamon raw ma-
terial as CCE, using the same extraction process.
In vitro inhibition of the pancreatic α-amylase enzyme
activity
Inhibition of α-amylase activity was assayed using the
enzymatic assay and reagents proposed by Sigma Aldrich.
Briefly, the pre-incubation mix was composed of 1.5 mL
of buffer (50 mmol/L sodium phosphate, 50 mmol/L
sodium chloride, 0.5 mmol/L calcium chloride, pH 6.9),
0.4 mL of the solutions to be tested containing the inhibi-
tors at different concentrations, and 0.1 mL of the enzym-
atic solution consisting of 100 U/mL of α-amylase from
porcine pancreas (Sigma Aldrich). It was pre-incubated
for 30 min at 25°C. Then, 0.5 mL of this pre-mix was in-
cubated with 0.5 mL of a substrate composed of 1% (w:v)
gelatinized potato starch (Sigma Aldrich) in 20 mmol/L
sodium phosphate buffer and 6.7 mmol/L sodium chloride
(pH 6.9) for 20 min at 25°C. The reaction was stopped by
the addition of 0.5 mL of a solution composed of sodium
potassium tartrate and 96 mmol/L 3,5-dinitrosalicylic
acid, then by boiling for 15 min, then by cooling on
ice. The absorbance was read at 540 nm. The assays
were conducted in triplicates. Acarbose (Sigma Aldrich)
was used as a positive control.
Acute starch tolerance test in the rat
Five-week old male Wistar Han IGS rats weighing
between 50 and 75 g were purchased from the Charles
Rivers Laboratories. Two rats were housed per cage.
Filtered tap water and regular animal non-purified diet
comprised of 51.7% carbohydrates, 21.4% proteins, and
5.1% lipids (diet A03, SAFE) were supplied ad libitum.
The animal room environment was controlled with a
temperature of 22 ± 2°C and day/night cycles of 12 hours
light, 12 hours dark (19:00–7:00). Animals were allowed
to acclimate to the laboratory environment for 10 days,
weighed 3 times per week, and randomly assigned to the
different study groups (8 to 20 animals per group depen-
ding on the study, as indicated in the figure legends). The
protocols were approved by the following ethics com-
mittee: “Comité Régional d’Ethique sur l’Expérimentation
Animale”, Pharmacology Laboratory, Pharmacy University,
15 Avenue Charles Flahault, 34093 Montpellier, France.Starch tolerance tests (STT) were conducted in animals
which had fasted overnight through the acute adminis-
tration by oral gavage of a 7.5% wheat starch solution at
1.5 g/kg or 20 mL/kg of body weight containing the prod-
ucts to be tested. The control group was administered
starch only. The actual volume administered to each rat
was calculated and adjusted based on the most recent body
weight of each animal. Blood samples were collected via
the tail vein before and 15, 30, 60, 90, and 120 min after
starch administration. One drop of blood was used for the
glucose determination using a hand-held glucometer
(OneTouch Ultra 2, LifeScan) and, when insulin was
measured, 50 μL of blood were withdrawn using heparin
as an anticoagulant for the plasma preparation. Insulin
concentrations were determined using an ELISA assay
(Ultrasensitive Mouse Insulin ELISA, Mercodia). At
the end of the studies, animals were euthanized by
CO2 inhalation.
Three studies were performed, all following this proto-
col and referred to in the following sections of the Results
section of this publication: effect of CCE at 50 mg/kg of
body weight on blood glucose and insulin response, dose-
effect of CCE at 6.25, 12.5, 25, 50, and 100 mg/kg of body
weight on blood glucose response and differences of
effects between hydro-alcoholic (CCE), and aqueous ex-
tracts at 50 mg/kg of body weight.
Human clinical trial
This clinical study was conducted by Naturalpha, a
Contract Research Organization (CRO), within their
facilities of the Clinic Nutrition Center, Hôpital Saint
Vincent de Paul, Lille, France. It consisted of a mono-
centric, randomized, double-blind, placebo-controlled,
crossover clinical trial which was approved by the Na-
tional Agency for Medicines and Health Products
Safety (ANSM, 143/147 boulevard Anatole France, 93285
Saint-Denis, France) and the Ethics Committee (CPP
Nord-Ouest III, CHU, avenue Côte de Nacre, 14033 Caen,
France).
The primary endpoint was the area under the curve
(AUC) 0–120 min of glycemia compared between
CCE and placebo after the absorption of a standard
meal. The secondary endpoints were the AUC 0–60 min
of glycemia, the AUC 0–120 and 0–60 min of insuli-
nemia, maximal glucose and insulin concentration,
glycemia and insulinemia values at each point in time.
The occurrence of adverse events (AE) was recorded
during the entire study. AE have been either spon-
taneously reported by the subjects, collected through
Investigator questioning, clinical examination or labo-
ratory testing, or from Investigator reviews of the
subject’s diary. The intensity of all AE was recorded
on the Case Report Form as ‘mild’, ‘moderate’ or
‘severe’.
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an informed consent form. Inclusion criteria included
age between 18 and 45, BMI between 18.5 (limit included)
and 25 kg/m2 (limit excluded), good physical condition,
and stable body weight within the last 3 months prior to
screening (<5% variation). Exclusion criteria included fast-
ing capillary blood glucose levels > 110 mg/dL, history of
diabetes, smokers, intake of dietary supplements or drugs
having an effect on glycemia and insulinemia. The sub-
jects were required to maintain the same lifestyle through-
out the study and to eat the same meal at dinner the
evening before the two tests. The subjects eligible for the
study in terms of inclusion and non-inclusion criteria had
an OGTT at the screening visit (V1) in order to exclude
subjects with atypical glycemic responses so as to have a
homogeneous healthy population with a minimal glycemic
response variation. After an overnight fast of at least
10 hours, subjects were given 50 g of glucose in 250 mL of
water to drink within a 3 minute timeframe. Capillary
blood samples were collected before and 15, 30, 45, 60, 90,
and 120 min after the glucose load. Subjects with fasting
capillary blood glucose levels > 110 mg/dL and/or 2 hours
postprandial capillary blood glucose levels > 140 mg/dL
were excluded from the study as well as subjects with
AUC <Mean AUC± 2 SD or AUC >Mean AUC ± 2 SD.
Every selected subject came to the clinical center after
one night of fasting to complete two study visits (V2 and
V3) at least 72 hours apart. Randomization and product
assignment occurred during V2. It was performed using
an allocation list prepared by a biostatistics company
(Biostatem, France). The subjects were assigned in a ran-
dom order to receive one of the following combinations:
CCE, then placebo or placebo, then CCE. With this
cross-over design, all subjects received both: the test
product and the placebo, in a random order. The al-
location list was used to label the study products
accordingly. The study products were packaged and
labeled by the Promoter (Dialpha, France), with the
packaging and labeling enabling unconditional double
blind administration by the individuals conducting the
trial (investigator and staff; Naturalpha, France) or the
subjects of the study.
The test product was delivered as two 500 mg capsules
of pure CCE. The matching placebo was provided in two
500 mg capsules, visually identical to the CCE and con-
taining a mix of 20% microcrystalline cellulose and 80%
di-calcium phosphate. The test meal consisted of 103 g
of white bread containing 52.2% of carbohydrates (of
which 3.6% of sugars), 7.4% of proteins, 0.1% of lipids,
and 3.3% of fibers (the bread thus corresponding to 50 g
of complex carbohydrates, i.e. carbohydrates equivalent
to three or more sugars). One drop of capillary blood
was used for glucose determination using a hand-held
glucometer (Accu-Check Performa, Roche). A catheterwas placed in the antecubital vein of the subject’s
arm to collect venous blood in dried tubes for serum
preparation for insulin measurement by ELISA (Unicel
DXi, Beckman). Capillary blood samples were collected
at −35 minutes prior to meal absorption to check the
fasting status (i.e. blood glucose levels ≤ 110 mg/dL).
The capsules (test product or placebo) were consumed
with 125 mL of water at −30 minutes. At 0 minutes, the
test meal was served with 250 mL of water for con-
sumption within a period of 8 minutes. Capillary and
venous blood samples were collected at −10, −5, 15, 30,
45, 60, 90, and 120 minutes. The averages of plasma
glucose levels at −10 and −5 minutes were used as
the fasting (time “zero”) glycemia value, whereas insulin
level at time −5 min was used as the fasting (time “zero”)
insulinemia value.
The study was regularly monitored to ensure execution
in accordance with the protocol, Good Clinical Practice
(GCP), and other applicable regulations. The person in
charge of monitoring reviewed and compared the Case
Report Form (CRF) entries with original source data in
order to check protocol adherence and to detect any data
inconsistency or discrepancy.
Statistical analyses
For the rat studies, statistical analyses were conducted
using Microsoft Excel software. Student’s t-test (two-
sample equal variance with a two-tailed distribution) was
executed as indicated in the legends of the figures. Values
of P < 0.05 were considered statistically significant when
comparing the control group to the treated group.
For the clinical trial, the required sample population
size was calculated considering a power of 80%, a standard
deviation of 25%, an expected difference between placebo
and CCE (based on in vivo CCE preclinical data) of 25%,
and using Student’s t table. According to these hypotheses,
18 subjects had to be enrolled in the trial. Statistical
analyses were performed on ITT (Intention To Treat) and
PP (Per Protocol) populations using SAS® software version
9.3. Since we were evaluating the ability of an active
extract to reduce the glycemic and insulinic responses to
white bread, we decided to measure the “net incremental
AUC”. The Net incremental AUC takes into account the
negative increments of the curve. The trapezoid rule is
applied for all increments, whether positive and negative.
All tests were two-sided and significance was declared at a
0.05 threshold. An analysis of variance was performed on
the AUC by testing the subject, period, and product ef-
fects. Global product effect was tested and, subsequently,
product comparisons were performed on CCE compared
to Placebo. The comparison tests followed the intra-
individual design using a paired Student’s t-test or a non-
parametric method in case of non-normality: the Koch



















Figure 1 Alpha-amylase inhibitory effect of CCE. Values represent
mean of triplicate measures.
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into account the period effect. First, the equality of resi-
dual effects was tested on the sum of the two periods, then
in case of no difference, the equality of direct effect
between CCE and Placebo was tested using the difference
of the two periods. The period effect could be tested using
the same test on the crossover difference.
Results
Inhibition of the pancreatic α-amylase enzyme activity
by CCE
CCE was tested for its ability to inhibit the activity of
the α-amylase from the porcine pancreas. Acarbose, a
well-known drug that inhibits α-glucosidase and α-
amylase activity, was used as positive control. Both CCE
and Acarbose inhibited mammalian α-amylase activity,
with an IC50 of 25 and 18 μg/mL respectively (Figure 1).A
Figure 2 Effect of CCE on blood glucose and insulin response during
weight on blood glucose response (A) and on insulin response (B) during
different from control, Student’s t-test *P < 0.05; **P < 0.01; ***P < 0.001.Effect of CCE on blood glucose and insulin response to
starch in the rat
The administration of 1.5 g/kg of body weight of starch
in rats fasting overnight induced a quick and significant
rise in glycemia, i.e. an increase of 73.5 ± 2.8 mg/dL above
the pre-STT value (T0) 30 min after the starch load
(Figure 2A). When added to starch, CCE at 50 mg/kg
of body weight reduced the glycemic response by 20.4%
compared to starch alone (AUC 0–120, P < 0.05). This ef-
fect is particularly significant during the peak of glycemia
at 30 min (Student’s t-test P < 0.001; Figure 2A).
Without the CCE and during the same lapse of time,
following the rise of glycemia-induced insulin secretion
by the pancreas, the blood insulin level quickly rose
reaching 2.3 ± 0.5 ng/mL above pre-STT value at the peak,
15 min after starch load (Figure 2B). With CCE, the insu-
lin peak (AUC 0–120 min) was blunted by 40.6%, reaching
1.0 ± 0.4 ng/mL above pre-STT value at 15 min. This
effect on insulin is statistically significant for the
AUC 0–60 min (P < 0.05) but not for the AUC 0–
120 min (P = 0.13).Dose-effect of CCE on blood glucose response to starch
in the rat
The dose–response of CCE was evaluated on blood
glucose levels during STT in normal fasting rats. CCE
reduced the glycemic response to starch in a dose-
dependent manner (Figure 3A). Compared to the con-
trol (starch alone), the AUC between 0 and 120 min was
reduced by 3.2%, 10.1%, 14.5%, 22.5%, and 30.7% with
CCE doses of 6.25, 12.5, 25, 50, and 100 mg/kg of
body weight, respectively. This effect is significant from
12.5 mg/kg of body weight (Student’s t-test P < 0.05). A
regression analysis of the dose–response of CCE were
performed. The best fit was obtained using logarithmic
equation (R2 = 0.99; Figure 3B) suggesting that CCE effectB
a STT in rats. Acute effect of CCE at the dose of 50 mg/kg of body
STT in normal rats. Values represent mean ± SEM, n = 8. Time points
A 
B 
Figure 3 Dose-effect of CCE on blood glucose during a STT in
rat. Acute dose-effect of CCE on blood glucose response during STT
in normal rats, (A) AUC 0–120 min, (B) Logarithmic regression of
CCE dose-effect. Values represent mean ± SEM, n = 8. AUC different
from control, Student’s t-test *P < 0.05; ***P < 0.001.
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kg of body weight.
Differences of effects between hydro-alcoholic and
aqueous extracts
The magnitude of effects on the reduction of glycemic
response to starch in rats with the hydro-alcoholic extract
(CCE; 14.9% reduction of AUC 0–60 min) is double com-
pared with the aqueous extract (7.8% reduction of AUC
0–60 min) (Figure 4A). The effect of CCE is significantly
higher at time point 15 min (P < 0.05), 30 min (P < 0.01),
and for the AUC 0–60 min (P < 0.05) compared to the
aqueous cinnamon extract.The effects obtained on the α-amylase inhibition in vitro
(Figure 4B) seem consistent with the effects obtained on
the glycemic response in the rat: the hydro-alcoholic ex-
tract (CCE; IC50 = 30 μg/mL) presented a stronger inhib-
ition than the aqueous extract (IC50 = 40 μg/mL).
Effect of CCE in human clinical trial
Twenty-two subjects were screened for this study. Three
subjects were declared non-eligible (blood glucose levels
or BMI not compliant with inclusion criteria) and one
subject was not included because the total number of
subjects required for the study was reached. In total, 18
randomized subjects were included in the crossover
study (Table 1). All 18 selected subjects completed the
study. Compliance with the treatment reached 100% and
no side effects were reported during the study. Two sub-
jects were excluded from Per Protocol statistical analyses
as they presented major deviations from the protocol
(delay within blood sampling time points and delay in
standard meal intake; the CONSORT flow diagram of
participants is described in Figure 5). Sequence effect
was investigated to compare “Product then Placebo” and
“Placebo then Product” sequences. No statistical differ-
ence between sequences was observed.
The intake of 1 g of CCE 30 minutes before the test
meal reduced the glycemic response to this test meal
compared to placebo (Figure 6A). CCE reduced the
AUC 0–120 min by 14.8%, although a significant differ-
ence was not reached (P = 0.15; Figure 6B). However, a
significant difference was observed at the peak of glycemia
corresponding to the AUC 0–60 min. In these first
60 min, the consumption of CCE was associated with a
21.2% reduction of blood glucose compared to placebo
(P < 0.05; Figure 6C). At the same time, no significant
difference was observed between groups regarding all
the other measured parameters, notably insulin response
(Figure 6D). These results suggest that CCE ingestion
prior to a standard meal helps limit the glucose response
in the 60 minutes following the meal absorption without
affecting insulin response.
Discussion
This study investigated for the first time the acute effect
of a Ceylon cinnamon water-ethanol extract on blood
glucose response to starch.
In vivo data provide evidence of the effect of CCE on
the reduction of postprandial glycemia following starch
administration in normal rats. The effect increased grad-
ually with the dose and is significant from 12.5 mg/kg of
body weight. Interestingly, at the same time, CCE also
tended to lower insulin response to starch, showing that
the effect of the extract is not due to a stimulation of insu-
lin secretion. Next to that, other experiments that we have
conducted in rats showed that if starch is being replaced
AB
Figure 4 Comparison of the effects of hydro-alcoholic and aqueous cinnamon extracts. (A) Blood glucose response during STT in normal
rats. Values represent mean ± SEM, n = 20. Student’s t-test: *P < 0.05; **P < 0.01; ***P < 0.001 different from control; #P < 0.05; ##P < 0.01 different
from aqueous cinnamon extract. (B) In vitro α-amylase inhibition. Values represent mean of triplicate measures.
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test, CCE has no effect on the glycemic response (data not
shown). These results indicate that CCE acutely inhibits
the digestion of starch in vivo but has no effect on thedigestion of disaccharides (maltose and saccharose), nor
on the passage of glucose from the intestine to the
blood stream. Also, CCE showed no acute effect on
glucose tolerance, i.e., the capacity of the body to
Table 1 Baseline characteristics of the healthy volunteers
n 18
Age (years) 29.9 ± 1.8
Gender 11 male/7 female
BMI (kg/m2) 21.4 ± 0.4
Heart rate (bpm) 67.8 ± 2.4
Systolic blood pressure (mmHg) 127.3 ± 2.7
Diastolic blood pressure (mmHg) 73.2 ± 2.4
Cross-over design. Values represent mean ± SEM.
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blood.
Taken together, these results support the fact that CCE
seems to specifically inhibit α-amylases. One published
study demonstrating the acute effect of a methanol Ceylon
cinnamon extract at 300 mg/kg of body weight on the gly-
cemic response to maltose and sucrose in rats suggested
an effect on alpha-glucosidase [27]. We could not repro-
duce these results with CCE at the dose of 50 mg/kg of
body weight, a dose which is clearly effective on starch
response and which constitutes, in our point of view, a
more physiological dose regarding further applications in
humans.
The effects of CCE on postprandial blood glucose and
insulin response were assessed in healthy male andAssessed for elig
Analysed (n= 16) 
♦ Excluded from analysis (n= 2) Two subjects were excluded 
major deviations from the protocol (delay within blood samplin
CCE 
Allocated to intervention (n= 9) 
♦ Received allocated intervention (n= 9)
Placebo 
Allocated to intervention (n= 9) 









Figure 5 Flow diagram of clinical study participants.female volunteers. Since the extract seems to act by inhi-
biting α-amylase enzymes, the first enzymes involved in
carbohydrate digestion, and since CCE was formulated
in capsules, we wanted to make sure that the capsules
would dissolve and that the enzymes would be inhibited
before the arrival of the test meal in the upper intestine.
For this reason, we decided to administrate the capsules
30 minutes before the meal consumption. In doing so,
1 g of CCE reduced the post-meal glycemic response
by ~ 20% and ~ 15% between 0 and 60 min and between
0 and 120 min post meal absorption respectively. This
effect is statistically significant (P < 0.05) at the peak of
glycemia between 0 and 60 min post meal absorption. In
this trial, we addressed young healthy volunteers with
normal glucose tolerance (IGT subjects were excluded at
screening). Accordingly, in these subjects, glycemia is
mainly increased between 0 and 60 min post meal absorp-
tion and returns to normal value between 60 and 120 min,
almost linearly (Figure 6A). In these conditions, it is
understandable that the effect of CCE is higher on the
peak where the “therapeutic window” is larger. By in-
creasing the number of subjects, our observed glycemic
response reduction could possibly also have become
statistically significant between 0 and 120 min. Another
option could have been to select IGT subjects presenting
an exacerbated glycemic response which remains elevated
until 2 hours after the meal absorption.ibility (n= 22) 
Excluded (n= 4) 
♦ Not meeting inclusion criteria (n= 3) 
♦ Number of subjects reached (n= 1) 
from Per Protocol statistical analyses as they presented 
g time points and delay in standard meal intake)
Placebo 
Allocated to intervention (n= 9) 
♦ Received allocated intervention (n= 9)
CCE 
Allocated to intervention (n= 9) 
♦ Received allocated intervention (n= 9)
on
sis







Figure 6 Effect of 1 g CCE on blood glucose and insulin response after a standard meal in humans. (A) Blood glucose concentration over
120 min, (B) Glycaemia AUC 0–120 min, (C) Glycemia AUC 0–60 min, and (D) Insulin concentrations over 120 min. Values represent mean ± SEM,
n = 16.% of inhibition of test meal glycemic response is indicated. CCE different from placebo, *P < 0.05.
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insulin response between CCE and placebo, showing
that the effect of CCE in reducing postprandial gly-
cemia does not seem to be due to a stimulation of insulin
secretion. This is consistent with the findings from
the rat study.
Regulatory bodies consider that the improvement of
post-prandial glycemia should not be accompanied by an
increase in insulinemia which is in accordance with this
clinical trial’s findings.
In conclusion, women and men who have taken
CCE have reduced their glycemia following the absorp-
tion of the test meal, yet with no variation of their insulin
demand.
Interestingly, as a side finding, this work allows us to
compare the acute effect of CCE, an α-amylase inhibitor
acting in the intestine, on the glycemic response to
starch in rats and in humans. To our knowledge, this
correlation is poorly described in existing literature. 1 g
of CCE (~12.5 mg/kg of body weight for a man weighing
75 kg) resulted in the reduction of the glycemic response
to starch in humans by 15 to 20%. Given that a dose of25 to 50 mg/kg of body weight is needed to observe
an equivalent reduction in the rat, it appears that the
human equivalent dose of CCE or, by extension, a “CCE-
like” α-amylase inhibitor, to the rat may be the dose effect-
ive in the rat divided by 2 to 4.
Here we tested the acute effect of a specific hydro-
alcoholic Ceylon cinnamon extract on postprandial
glycemia. This is a new discovered property of cinna-
mon extracts which are usually recognized for their
chronic effect on glycemia. Other investigators have
tested the effect of up to 6 g of raw cinnamon bark
powder on the glycemic response in human clinical
trials. No effect was observed with Ceylon cinnamon
[28,29] whereas cassia cinnamon presented significant
effect in 2 studies [30,32].
These interesting results bring us to another important
consideration regarding the safety of cinnamons and
their derived extracts with respect to their levels of couma-
rin, a potentially toxic molecule [18]. Ceylon cinnamon
contains only traces of coumarin and the corresponding
extract, even using ethanol as the extraction solvent, con-
tains far less coumarin amounts than the tolerable daily
Beejmohun et al. BMC Complementary and Alternative Medicine 2014, 14:351 Page 10 of 11
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(0.1 mg/day/kg of body weight; 7 mg/day for a person of
70 kg). The CCE coumarin contents is less than 200 mg/kg
(i.e. 1 g of CCE/day contains less than 0.2 mg/day of cou-
marin). The coumarin content in the CCE batch used for
the clinical trial was 112 mg/kg. For the cassia species
however, coumarin levels are of concern [19]. Furthermore,
since coumarin is more alcohol soluble than water soluble,
an ethanol extract of this species would enrich the extract
in coumarin, thus worsening coumarin related problem
altogether. An aqueous extraction of the Cinnamomum
cassia species would allow to reduce the level of coumarin
contained in the raw material. However, according to
the in vitro results on α-amylase inhibition and as evi-
denced by the in vivo results on starch tolerance tests in
rats, CCE was significantly more efficient than an aqueous
cinnamon extract.
Taken all together, these results show that a hydro-
alcoholic Ceylon cinnamon extract appears to be an
optimal solution in terms of coumarin content and efficacy
as far as cinnamon extracts for use in the management of
postprandial glycemia are concerned.Conclusions
In summary, this study demonstrates that a well-defined
hydro-alcoholic Ceylon cinnamon bark extract reduces
the glycemic response to starch in normal rats and
healthy male and female subjects by inhibiting pancre-
atic α-amylase starch digestion. This extract may be of
great interest with regards to the many recognized bene-
fits associated with the reduction of postprandial hyper-
glycemia. These benefits namely include reducing the
risk of developing type 2 diabetes in people with IGT,
helping with the lipid profile management, helping with
the control of fat mass, body weight, and oxidative
stress, and finally helping reduce the risk for cardiovas-
cular diseases occurring. Other human clinical trials will
be required to confirm these results on postprandial gly-
cemia and in order to directly assess the other health
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